ATNM - Actinium Pharmaceuticals Inc Stock Price, Fair Value and News

7.83USD-0.07 (-0.89%)Market Closed

Market Summary

USD7.83-0.07

Market Closed

-0.89%

ATNM Stock Price

View Fullscreen

ATNM RSI Chart

ATNM Valuation

Market Cap

233.2M

Price/Earnings (Trailing)

-5.02

Price/Sales (Trailing)

2.7K

Price/Free Cashflow

-5.87

ATNM Price/Sales (Trailing)

ATNM Profitability

Return on Equity

-105.91%

Return on Assets

-52.57%

Free Cashflow Yield

-17.03%

ATNM Fundamentals

ATNM Revenue

Revenue (TTM)

81.0K

ATNM Earnings

Earnings (TTM)

-46.5M

Earnings Growth (Yr)

21.45%

Earnings Growth (Qtr)

7.01%

Breaking Down ATNM Revenue

Last 7 days

10.1%

Last 30 days

6.2%

Last 90 days

14.0%

Trailing 12 Months

13.3%

How does ATNM drawdown profile look like?

ATNM Financial Health

Current Ratio

10.59

ATNM Investor Care

Shares Dilution (1Y)

12.77%

Diluted EPS (TTM)

-1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	555.5K	0	0	81.0K
2022	1.5M	1.2M	1.1M	1.0M
2021	0	690.2K	917.1K	1.1M
2012	236.5K	463.4K	0	0
2011	0	20.1K	14.9K	9.6K
2010	0	0	0	25.4K

Get all data in R, Python etc through our Historical Stock Data APIs

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

CEO	Mr. Sandesh C. Seth M.B.A., M.S., MBA
WEBSITE	actiniumpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	49

Actinium Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Actinium Pharmaceuticals Inc? What does ATNM stand for in stocks?

ATNM is the stock ticker symbol of Actinium Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Actinium Pharmaceuticals Inc (ATNM)?

As of Fri Jul 26 2024, market cap of Actinium Pharmaceuticals Inc is 233.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNM stock?

You can check ATNM's fair value in chart for subscribers.

Is Actinium Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ATNM is over valued or under valued. Whether Actinium Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Actinium Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNM.

What is Actinium Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ATNM's PE ratio (Price to Earnings) is -5.02 and Price to Sales (PS) ratio is 2.73 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Actinium Pharmaceuticals Inc's stock?

In the past 10 years, Actinium Pharmaceuticals Inc has provided -0.28 (multiply by 100 for percentage) rate of return.